Immunohistochemical study of chondroitin-6-sulphate and tenascin in the larynx: a loss of chondroitin-6-sulphate expression accompanies squamous cell carcinoma invasion.
Chondroitin 6-sulphate is a glycosaminoglycan component of both cell membrane and basement membrane proteoglycans. In vitro it can inhibit tenascin, a molecule critical for epithelial cell migration during development and in wound healing. The immunohistochemical expression of chondroitin-6-sulphate and tenascin has been examined in 143 laryngeal biopsies from 38 patients, with particular attention to changes occurring with squamous cell carcinoma invasion. All tissues were formalin-fixed and paraffin-embedded. An avidin-biotin complex immunoperoxidase technique was used. Immunostaining for chondroitin-6-sulphate was seen in the basement membrane and/or cell membranes of basal and suprabasal cells of the laryngeal epithelium. Immunostaining of cell or basement membrane was seen at least focally in 67 of 71 (94 per cent) biopsies with no atypia, in 39 of 45 (87 per cent) biopsies with mild/moderate atypia, and in 16 of 16 (100 per cent) biopsies with severe dysplasia or carcinoma in situ (CIS); but in only 2 of 18 biopsies with invasion, although in neither of these was chondroitin-6-sulphate immunostaining seen at the actual site of invasion. Tenascin immunostaining was seen along the basement membrane in all biopsies. Those with CIS or invasion showed, in addition, strong tenascin staining of the adjacent stroma. The loss of chondroitin-6-sulphate immunostaining concurrent with squamous cell carcinoma invasion in the larynx suggests that loss of a chondroitin-6-sulphate-containing proteoglycan, or a change in proteoglycan side-chain composition, is a critical step in laryngeal epithelial tumour invasion.
Uhlman
D L
DL
Hubert H. Humphrey Cancer Center, 3300 Oakdale Ave., Robbinsdale, MN 55422, USA.
Niehans
G A
GA
D015415:Biomarkers / Q000032:analysis; D002278:Carcinoma in Situ / Q000737:chemistry / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000473:pathology; D002809:Chondroitin Sulfates / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D007822:Laryngeal Neoplasms / Q000737:chemistry* / Q000473:pathology; D008297:Male; D009361:Neoplasm Invasiveness; D019063:Tenascin / Q000032:analysis*
D015415:Biomarkers; D019063:Tenascin; D002809:Chondroitin Sulfates